{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen R"],"funding":["Chinese Academy of Medical Sciences &amp; Peking Union Medical College","Fundamental Research Funds for Central Public-interest Scientific Institution","National Natural Science Foundation of China","Shenzhen Key Medical Discipline Construction Fund","Sanming Project of Medicine in Shenzhen"],"pagination":["1482"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9599865"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(10)"],"pubmed_abstract":["<i>Background.</i> In vivo studies show that LL-37 inhibits the progression of atherosclerosis and predicts a lower risk of recurrent ischemia in patients with acute myocardial infarction (AMI), which could be mediated by the modulation of lipid metabolism. The current study aimed to investigate the effects of various lipid contents on the prognostic impacts of LL-37 in patients with AMI. <i>Methods.</i> A total of 1567 consecutive AMI patients were prospectively recruited from March 2017 to January 2020. Patients were firstly stratified into two groups by the median level of LL-37 and then stratified by levels of various lipid contents and proprotein convertase subtilisin/kexin type 9 (PCSK9). Cox regression with multiple adjustments was performed to analyze associations between LL-37, li"],"journal":["Biomolecules"],"pubmed_title":["Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study."],"pmcid":["PMC9599865"],"funding_grant_id":["2012-F25","SZXK001","2016-I2M-1-009","81970308","SZSM201911017"],"pubmed_authors":["Song L","Li J","Zhou P","Chen Y","Liu C","Wang Y","Chen R","Yan H","Zhao H","Zhou J","Zhao X","Li N"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study.","description":"<i>Background.</i> In vivo studies show that LL-37 inhibits the progression of atherosclerosis and predicts a lower risk of recurrent ischemia in patients with acute myocardial infarction (AMI), which could be mediated by the modulation of lipid metabolism. The current study aimed to investigate the effects of various lipid contents on the prognostic impacts of LL-37 in patients with AMI. <i>Methods.</i> A total of 1567 consecutive AMI patients were prospectively recruited from March 2017 to January 2020. Patients were firstly stratified into two groups by the median level of LL-37 and then stratified by levels of various lipid contents and proprotein convertase subtilisin/kexin type 9 (PCSK9). Cox regression with multiple adjustments was performed to analyze associations between LL-37, li","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-19T12:05:01.327Z","creation":"2024-12-04T00:14:33.943Z"},"accession":"S-EPMC9599865","cross_references":{"pubmed":["36291690"],"doi":["10.3390/biom12101482"]}}